Therapy Areas: Autoimmune
IMIDomics and Gossamer Bio Enter into a Strategic Collaboration to Advance the Development of Novel Treatments for Patients with Immune-Mediated Inflammatory Diseases
5 February 2020 - - Spain-based clinical analytics platform developer IMIDomics S.L. has entered into a strategic collaboration with Gossamer Bio, Inc., to advance the discovery and development of novel treatments to address patients with Immune-Mediated Inflammatory Diseases (IMIDs), the company said.

IMIDs affect large populations across the globe, are chronic and costly conditions, and affect patients in the prime of their lives.

They constitute a broad class of diseases, including inflammatory bowel disease, multiple sclerosis, psoriatic arthritis, rheumatoid arthritis, psoriasis, and systemic lupus erythematosus, in which dysregulation of the immune response leads to inflammatory pathophysiology and ultimately tissue destruction.

The collaboration will give Gossamer's world-class immunology research and development team the ability to benefit from IMIDomics' unique clinical and molecular patient database to ultimately inform product discovery and development strategy.

The agreement allows Gossamer to select and collaborate with IMIDomics on multiple projects, the first project being in the field of inflammatory bowel disease.

IMIDomics provides critical insights for treating patients with Immune-Mediated Inflammatory Diseases (IMIDs).

IMIDomics' comprehensive platform integrates access to a dynamic and high quality IMID patient biobank, corresponding curated clinical data, associated proprietary multiomics molecular data and world-class clinical expertise.

The company's analytics platform extracts unique insights into disease biology and patient conditions through our proprietary interactive portal. IMIDomics' unique capabilities result in novel insights that drive drug discovery and development, and guide precision treatment of patients.
Login
Username:

Password: